You are here: Industry Insights > Xalkori

News List

Pfizer gets USFDA nod for XALKORI (crizotinib) to treat ALK-positive ALCL in children and young adults expresspharma
January 15, 2021
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people.
FDA grants priority review for Pfizer’s Xalkori in paediatric ALCL pharmaceutical-technology
September 27, 2020
Pfizer has secured priority review from the US Food and Drug Administration (FDA) for Xalkori (crizotinib) to treat relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) in children.
NICE backs Takeda’s Alunbrig in second-line lung cancer pharmaphorum
February 18, 2019
NICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive advanced non-small cell lung cancer, in patients already treated with Pfizer’s Xalkori.
EU green light for Takeda’s Alunbrig pharmatimes
November 28, 2018
Takeda’s Alunbrig has been approved in Europe as a treatment for a specific group of lung cancer patients, but access to the drug in the UK remains uncertain.
Pfizer snags OK for Xalkori follow-up Lorbrena in its 3rd cancer approval in 2 months fiercepharma
November 06, 2018
Pfizer’s oncology unit is on a roll. On Friday, the FDA approved its third cancer-fighter from the New York drugmaker in the past two months, setting it up to mount a double-barreled challenge in ALK-positive non-small cell lung cancer.
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy pharmatimes
September 27, 2018
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC pharmatimes
July 27, 2018
Takeda’s Alunbrig has beaten Pfizer's Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Pfizer's Xalkori receives FDA breakthrough therapy designation biospectrumasia
June 01, 2018
If approved in patients with metastatic NSCLC with MET exon 14 alterations, XALKORI will be the only TKI with demonstrated efficacy in three separate biomarker-driven indications in NSCLC.
ROS1 cancer patients team up to build disease models fiercebiotech
August 16, 2017
ROS1ders is working with collaborators to create mouse models and cell lines.